Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Former Italian foreign minister convicted for role in sale of Monte Carlo apartment
Xi Holds Talks with European Council President
Memorial Meeting for Comrade Jiang Zemin to Be Held on Dec. 6
Chinese National Flag Flown at Half
Jaguars cut WR Zay Jones, clearing a path to potentially sign five
Coach Cai vows to bring China women's volleyball team to Paris Olympics
Xi Says China to List Saudi Arabia as Destination for Group Travel
Full Text of Xi's Written Speech at APEC CEO Summit
EPA rule bans toxic chemical methylene chloride, toxic solvent known to cause liver cancer
Profile: Jiang Zemin's Great, Glorious Life
What's causing the catastrophic rainfall in Kenya?
Xi's Mideast Trip to Open up New Prospects for China